Navigation Links
Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
Date:9/8/2008

REF="http://www.oncolyticsbiotech.com" target="_new">http://www.oncolyticsbiotech.com

The Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio is among the nation's leading academic research and treatment centers, serving more than 4.4 million people in the high-growth corridor of Central and South Texas including Austin, San Antonio, Laredo and the Rio Grande Valley. CTRC is one of a few elite cancer centers in the country to be named a National Cancer Institute (NCI) Designated Cancer Center, and is one of only three in Texas. CTRC handles more than 120,000 patient visits each year and is a world leader in developing new drugs to treat cancer. The CTRC Institute for Drug Development (IDD) is internationally recognized for conducting the largest oncology Phase I clinical drug trials program in the world, and participated in the clinical and/or preclinical development of many of the cancer drugs approved by the U.S. Food & Drug Administration. For more information, visit our Web site at http://www.ctrc.uthscsa.edu.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the U.S. Phase 2 combination REOLYSIN(R)/paclitaxel and carboplatin clinical trial, and the Company's belief as to the potential of REOLYSIN(R) as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN(R) as a cancer treatment, the tolerability of REOLYSIN(R) outside a controlled test, the success and timely completion of clinical
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. /R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/
2. Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours
3. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
4. Oncolytics Biotech Inc. Announces 2008 Second Quarter Results
5. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
6. Oncolytics Biotech Inc. Announces U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Oncolytics Biotech Inc. to Present at BIO 2008 International Convention
8. Oncolytics Biotech Inc. Announces Start of Enrolment in Phase 1/2 Ovarian Cancer Clinical Trial with REOLYSIN(R)
9. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
10. Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting
11. Oncolytics Biotech Inc. Collaborators to Present Reovirus Research at ASGT Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)...  The University of California, San Diego,s Center ... San Diego Extension announced their third annual workshop ... – 14, 2015, at UC San Diego (see ... intense exposure to best practices and the latest ... biologists, process engineers and business executives planning next ...
(Date:6/30/2015)... Dr. Samadi Prostate Cancer Center in New York ... new genetic testing methods for men with an elevated PSA ... Dr. Samadi,s Prostate Cancer Center is ... and optimizing the diagnosis of prostate cancer, both pre-biopsy and ... these revolutionary genetic tests to men with an elevated PSA ...
(Date:6/30/2015)... ... June 30, 2015 , ... ... media company, launched “Cannavoices,” an unprecedented digital video and broadcast initiative. Produced by ... the most dynamic collection of legal medical cannabis stories ever assembled. , ...
(Date:6/29/2015)... and Manhattan, KS (PRWEB) , ... June 29, ... ... acquired US PATENT 7736892 B2. Under the terms of the agreement, MediVet will ... Cord Matrix Stem Cells (UCMSCs). MB-007 is currently in pre-clinical development as a ...
Breaking Biology Technology:UC San Diego Extension to Offer Third Annual Microbial Fermentation Workshop 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 2New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 3New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 4New Revolutionary Genetic Testing for Prostate Cancer Offered at Dr. Samadi's Prostate Cancer Center 5Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 2Cannavoices Launches a Legal Medical Cannabis Documentary Initiative 3MediVet Biologics Acquires Exclusive Patent License from Kansas State University 2MediVet Biologics Acquires Exclusive Patent License from Kansas State University 3
... www.tedmed.com , the world,s leading multi-disciplinary conference on the future ... of the conference will take place in Washington, DC at ... April 11-13, 2012. From 2009 to 2011, San ... and technology developers. The move to the Nation,s Capital and ...
... -- Andrew Barron, Rice University,s Charles W. Duncan, Jr. ... science, is the winner of the prestigious 2011 World ... the World Technology Summit and Awards gala at the ... the application of nanotechnology to fundamental problems in energy ...
... VetNostic Laboratories® offers state-of-the-art genetic testing services for ... are able to accurately and specifically determine whether ... reliable identification of these "carriers" ensures healthy litters ... VetNostic Laboratories® is pleased to introduce two new ...
Cached Biology Technology:TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 2TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 3TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 4TEDMED Announces Move to Washington, DC; the John F. Kennedy Center for Performing Arts Will Host TEDMED 2012 Conference 5Rice's Barron wins World Technology Award for Materials 2VetNostic Laboratories® Announces New Testing for Dog Breeds 2VetNostic Laboratories® Announces New Testing for Dog Breeds 3
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - ... partnership centralized around the incorporation of handyem,s HPC-150 ... diagnostic laboratory, the Mo-POD™. This unprecedented model of ... International Conference at the Pennsylvania ... from June 15 th to 18 th ...
(Date:6/16/2015)... Fingerprint Cards (FPC) raises the revenue guidance for ... at least 340 MSEK to that it will amount to ... growth and orders received the revenue guidance for 2015 is ... will exceed 1,500 MSEK to an updated guidance that revenue ... Due to receipt of orders of touch fingerprint sensors with ...
(Date:6/15/2015)... --NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company") ... market, announces that its leading payment security technology, the Wocket® ... @ NYC June 18th. Digital Experience! @ NYC ... technology to over 300 of the top media covering the ... in New York City from 6:00 ...
Breaking Biology News(10 mins):handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... cells become after being exposed to a specialized electrical ... cancerous or a stage of cancer already invading other ... the electrical process and found cells that expanded the ... disease has spread beyond its point of origin. The ...
... power to constrict blood vessels and help patients manage ... more about how endothelin functions naturally and in disease ... Despite strong laboratory evidence that blocking endothelin-1 receptors would ... health problems, the drugs failed patients, says Dr. Adviye ...
... Within the last few years the number of ... increased considerably. A worthwhile effort as, after all, it concerns ... of transport checks are offered by terahertz radiation. Before this ... to be measured quantitatively, so that damage to health caused ...
Cached Biology News:Expanding cell girth indicates seriousness of breast cancer 2Better understanding of blood vessel constrictor needed to harness its power for patients 2Checking people at airports -- with terahertz radiation 2
... containing an overproducing clone of M-MLV Reverse ... the polymerization of DNA using template DNA, ... large mRNAs, >10 kb, may be synthesized. ... RNase H activity than AMV Reverse Transcriptase ...
... catalyzes the template-directed polymerization of nucleotides into ... Polymerase I possesses a 3?5 exonuclease activity ... rate during DNA replication, and also contains ... enzyme to replace nucleotides in the growing ...
Request Info...
... yeast/leuconostoc overproducer ATP: D-hexose 6- ... One unit of HK will ... in 1 min at 25C ... of G6P-DH will oxidize 1 ...
Biology Products: